老年起病炎症性肠病的疾病进展:基于人群队列研究的系统综述与Meta分析
该系统综述与Meta分析纳入9项基于人群的队列研究、共14,765例老年起病(EO)IBD患者,评估其住院、手术、死亡、治疗模式及恶性肿瘤等累积风险,并与同队列成年起病(AO)IBD患者比较。结果显示EO IBD手术风险与AO IBD相似,但免疫调节剂和生物制剂暴露显著更低;EO IBD死亡率可能高于一般人群,但恶性肿瘤风险未见增加。
要点
- 老年起病克罗恩病5年手术累积风险22.6%,与成年起病者相似(RR 1.04)。
- 老年起病IBD免疫调节剂和生物制剂暴露显著低于成年起病IBD。
- 老年起病IBD死亡率可能高于一般人群,但恶性肿瘤风险未见增加。
核心结论
- 老年起病IBD患者的手术风险与成年起病IBD患者相似。
- 老年起病IBD患者接受免疫调节剂或生物制剂治疗的可能性更低。
- 老年起病IBD患者死亡率可能高于一般人群,但恶性肿瘤风险未见增加。
研究设计与样本
- 系统综述与随机效应Meta分析,检索截至2019年6月1日。
- 纳入9项基于人群的队列研究,共14,765例老年起病IBD患者。
- 比较老年起病与同队列成年起病IBD患者的1年、5年和10年累积事件风险。
主要发现
- 老年起病克罗恩病5年手术累积风险22.6%(95%CI 18.7-27.2),与成年起病克罗恩病相似(RR 1.04;95%CI 0.80-1.34)。
- 老年起病克罗恩病5年免疫调节剂暴露风险31.5%(95%CI 29.7-33.4),显著低于成年起病(RR 0.62;95%CI 0.51-0.77)。
- 老年起病克罗恩病5年生物制剂暴露风险6.5%(95%CI 5.6-7.6),显著低于成年起病(RR 0.36;95%CI 0.25-0.52)。
- 老年起病溃疡性结肠炎5年手术累积风险7.8%(95%CI 5.0-12.0),与成年起病相似(RR 1.29;95%CI 0.79-2.11)。
- 老年起病溃疡性结肠炎5年免疫调节剂暴露风险16.1%(95%CI 15.0-17.2;RR 0.58;95%CI 0.54-0.62)和生物制剂暴露风险2.0%(95%CI 1.6-2.5;RR 0.36;95%CI 0.24-0.52)均显著低于成年起病。
关键数值与推荐
- 老年起病克罗恩病5年皮质类固醇暴露风险55.4%(95%CI 53.4-57.4),与成年起病相当(RR 0.88;95%CI 0.78-1.00)。
- 老年起病溃疡性结肠炎5年皮质类固醇暴露风险57.2%(95%CI 55.6-58.7),与成年起病相当(RR 0.98;95%CI 0.91-1.06)。
临床怎么用
- 对老年起病IBD患者应评估手术风险,其手术风险与成年起病者相似。
- 老年起病IBD患者免疫调节剂和生物制剂使用不足,需关注治疗不足问题。
- 老年起病IBD患者应关注死亡率风险,但恶性肿瘤风险未见增加。
局限性
- 关于合并症或药物不良反应的数据很少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The incidence of inflammatory bowel diseases (IBDs) in older adults is increasing. We performed a systematic review and meta-analysis to evaluate progression of elderly onset (EO) IBD in population-based cohorts and compared it with adult onset (AO) IBD. METHODS: In a systematic review through June 1, 2019, we identified population-based cohort studies of EO IBD reporting the cumulative risk of hospitalization, surgery, mortality, treatment patterns, escalation, and/or malignancy. Data were synthesized using random-effects meta-analysis as cumulative risk of events at 1 year, 5 years, and 10 years, and compared with data from patients with AO IBD in the same cohorts. RESULTS: We identified 9 studies, comprising 14,765 patients with EO IBD. In patients with EO Crohn's disease (CD), the cumulative 5-year risk of surgery was 22.6% (95% CI, 18.7-27.2) and was similar to that of patients with AO CD (relative risk [RR], 1.04; 95% CI, 0.80-1.34). Overall exposure to corticosteroids was comparable between patients with EO CD vs AO CD (5-year risk: 55.4%; 95% CI, 53.4-57.4; RR, 0.88; 95% CI, 0.78-1.00), but exposure to immunomodulators (31.5%; 95% CI, 29.7-33.4; RR, 0.62; 95% CI, 0.51-0.77) or biologic agents (6.5%; 95% CI, 5.6-7.6; RR, 0.36; 95% CI, 0.25-0.52) was significantly lower for patients with EO CD than for patients with AO CD. Similarly, in patients with EO ulcerative colitis (UC), the cumulative 5-year risk of surgery was 7.8% (95% CI, 5.0-12.0), similar to the risk for patients with AO UC (RR, 1.29; 95% CI, 0.79-2.11). Overall exposure to corticosteroids was comparable between patients with EO UC vs AO UC (5-year risk: 57.2%; 95% CI, 55.6-58.7; RR, 0.98; 95% CI, 0.91-1.06), but exposure to immunomodulators (16.1%; 95% CI, 15.0-17.2; RR, 0.58; 95% CI, 0.54-0.62) or biologic agents (2.0%; 95% CI, 1.6-2.5; RR, 0.36; 95% CI, 0.24-0.52) was significantly lower for patients with EO UC than for patients with AO UC. Patients with EO IBD appeared to have increased mortality, but not malignancy, compared with the general population. There were few data on comorbidities or adverse effects of medications. CONCLUSIONS: In a systematic review and meta-analysis, we found that patients with EO IBD have a similar risk of surgery as patients with AO IBD. However, patients with EO IBD are less likely to receive treatment with immunomodulators or biologic agents.
引用
- Rozich JJ, Dulai PS, Fumery M, et al. Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. Clin Gastroenterol Hepatol. 2020. PMID: 32142940. doi:10.1016/j.cgh.2020.02.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。